HAMSAB: a plant-based food supplement improve immune system in individuals with type 1 diabetes


A microbiota-targeted clinical trial performed by scientists from Monash University, the University of Sydney, and the University of Queensland shows that a plant-based food supplement could improve gut health and strengthen the immune system in individuals with type 1 diabetes.

Senior author and lead investigator of the clinical trial, Dr. Eliana Marino from Monash University, said the study tested twenty-one adults with type 1 diabetes that incorporated a six-week supplement into their daily diet.

As a result, they showed increased production of metabolites called short-chain fatty acids by the gut microbiota, which has an important role in preventing type 1 diabetes.

“People with 1 diabetes have shown altered gut microbiota and reduced production of short-chain fatty acids in stools and blood. We previously have demonstrated that the supplement used in this human study protected mice from diabetes (Marino et al., Nat Immunol 2017),” said Dr. Marino.

The clinical trial published online January 19, 2022, in Microbiome showed that participants’ blood immune cells developed a more regulatory phenotype post-intervention.

Short-chain fatty acids (SCFAs) are metabolites produced by the gut microbiota, that greatly affect human health and disease [1]. Mostly produced from fermentation of non-digestible dietary carbohydrates, SCFAs, primarily acetate, propionate, and butyrate, are anti-inflammatory and critical for maintaining gut homeostasis as well as playing a role in host energy metabolism [2].

Reduced SCFA production is an indicator of a loss of beneficial bacteria (dysbiosis), which is commonly associated with chronic autoimmune and inflammatory diseases including type 1 diabetes (T1D) and type 2 diabetes [3, 4].

Indeed, studies in mice and humans have shown that a deficiency in production of SCFAs by the gut microbiota is associated with the development of T1D, starting well before clinical diagnosis [5,6,7,8], which may be linked to altered gut homeostasis [9,10,11].

Insufficient intake of dietary fiber, or a gut microbiota that is poor at SCFA production may underpin the increased incidence of T1D and many other Western diseases [1, 2]. Thus, a microbiota-targeted dietary intervention that tackles the underlying functional dysbiosis (i.e., deficiency of SCFAs and altered microbiota function) may have great potential in humans to prevent or treat T1D, as it does in autoimmune diabetes-prone nonobese diabetic (NOD) mice [5].

Clinical studies have begun to show the potential of modulating the microbiota composition via the use of prebiotics, probiotics, and fecal transplantation as an alternative approach to treat inflammatory diseases [12]. Most microbiota-based therapies identify bacterial communities or pathways associated with disease and then aim to restore specific health-associated species, an approach with inherent caveats.

For example, the wide inter-individual variability in the gut microbiota associated with diseases such as T1D [3, 7] and key factors such as diet and host genetics, which affect microbiota colonization and adaptation, are all barriers to current investigative approaches [13].

Post-biotic targets (metabolites produced by the gut microbiota) have recently emerged as a novel alternative to promote health and circumvent these barriers [14]. We have developed a high-SCFA–yielding dietary supplement that ameliorates gut infection, improves chemotherapy efficacy, and protects mice against T1D via regulating the immune system [5, 10, 15].

The SCFA-based supplement is a type 2–resistant starch consisting of a high-amylose (70%) maize starch (HAMS) that has been modified by bonding the acetate and butyrate (HAMSAB). It is resistant to digestion in the upper gastrointestinal tract, delivers a very high yield of SCFAs in the colon, and is a powerful tool to assess the effects of SCFAs on intestinal biology [5, 10, 15, 16].

The HAMSAB diet prevented beta-cell destruction by T cells and protected against T1D in 90% of NOD mice. Protection against T1D was associated with microbiota composition changes. The mechanism behind this SCFA-induced T1D protection involved synergistic effects of acetate and butyrate; expansion of regulatory T cells (Treg) was butyrate dependent, and a decrease in pathogenic B cells and CD4+ and CD8+ T cells was acetate dependent [5]. Therefore, this dietary intervention targets microbiota–host interactions, nutrition, and phylogeny.

Several human studies support the positive effects of increasing total fiber consumption in the form of high-amylose maize-resistant starch (HAMS) or butyrate-yielding HAMS (HAMSB) supplementation alone in glycemic control [17, 18] or gastrointestinal conditions [19,20,21].

We report the first interventional study in humans with T1D to determine the effects of delivering a combination of dietary acetate and butyrate on the immune system via the gut microbiota. We therefore, conducted a single-arm pilot-and-feasibility study using HAMSAB administered for 6 weeks with follow-up at 12 weeks in adults with long-standing T1D.

More information: Kirstine J. Bell et al, Metabolite-based dietary supplementation in human type 1 diabetes is associated with microbiota and immune modulation, Microbiome (2022). DOI: 10.1186/s40168-021-01193-9


Please enter your comment!
Please enter your name here

Questo sito usa Akismet per ridurre lo spam. Scopri come i tuoi dati vengono elaborati.